Generic-drug maker and IBD 50 stock Akorn (AKRX) reported Q4 earnings and gave 2015 guidance above consensus Thursday, sending the stock up nearly 12% on the stock market today to a new high near 52. Akorn’s earnings excluding one-time items jumped 257% over the year-earlier quarter to 50 cents a share, topping analysts’ consensus by 5 cents, according to Thomson Reuters. Sales climbed 168% to $227.8 million, about $10 million above the Street’s
Shares of generic drugmaker Lannett (LCI) climbed 7% on the stock market today, clearing a cup base buy point. Industry group peer Akorn (AKRX) cleared an area of consolidation earlier this month. For details on Lannett’s buy range, and other information about this top-rated stock, make sure to check out this video. Follow Alissa Williams on Twitter: @IBD_AWilliams.
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends working in its favor. As reported last month in IBD, the Lake Forest, Ill.-based company has a competitive advantage over many rivals due to its area of specialization. Akorn specializes in